Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 01 12 2018
accepted: 22 04 2019
pubmed: 29 4 2019
medline: 15 12 2020
entrez: 29 4 2019
Statut: ppublish

Résumé

To evaluate the clinical significance of invasive urothelial carcinoma that is ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor (TURBT). All consecutive in-house TURBTs with invasive urothelial carcinoma from 1999 to 2017 that underwent radical cystectomy (RC) were grouped as follows: invasion of the lamina propria (INLP; n = 102; 24%), invasion of muscularis propria (INMP; n = 296; 69%) and ambiguous for muscularis propria invasion (AMP; n = 30; 7%). AMP was defined as extensive invasive carcinoma displaying thin muscle bundles where it is difficult to determine with certainty if those muscle bundles represent muscularis mucosae or muscularis propria (detrusor). Cases with any amount of small cell carcinoma or prior therapy were excluded. The average age was 66 years in INLP, 67 years in INMP, and 65 years in AMP. RC showed invasive carcinoma stage pT2 or above in 50/102 (49%) of INLP vs. 255/296 (86%) of INMP (P ≤ 001) vs. 25/30 (83.33%) of AMP (P = 0.002). Lymph nodes showed metastatic carcinoma in 18/98 (18.36%) of INLP vs. 96/272 (35.29%) of INMP (P = 0.002), and 6/25 (24%) in AMP (P = 0.729). The average follow-up was 48 months (range 0-192). Survival of AMP patients was similar to INLP and both were significantly better than INMP (P = 0.002 and P = 0.016). The great majority of patients with AMP on initial TURBT have advanced disease on RC and emphasizes the need for early repeat TURBT or even consideration of early cystectomy to lower the risk of worse pathological findings and to prolong survival.

Identifiants

pubmed: 31030230
doi: 10.1007/s00345-019-02782-y
pii: 10.1007/s00345-019-02782-y
pmc: PMC6815684
mid: NIHMS1044341
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

389-395

Subventions

Organisme : NCI NIH HHS
ID : T32 CA193145
Pays : United States

Références

Eur Urol. 2013 Feb;63(2):321-32
pubmed: 23088996
Urology. 2009 Dec;74(6):1276-80
pubmed: 19758684
Eur Urol. 2010 May;57(5):843-9
pubmed: 19524354
Eur Urol. 2013 Jan;63(1):16-35
pubmed: 23083804
Clin Genitourin Cancer. 2016 Feb;14(1):e43-7
pubmed: 26363827
BJU Int. 2014 Jun;113(6):900-6
pubmed: 24053569
Adv Anat Pathol. 2017 May;24(3):113-127
pubmed: 28398951
Am J Surg Pathol. 2009 Jan;33(1):91-8
pubmed: 18936687
Virchows Arch. 2011 Jun;458(6):665-70
pubmed: 21494761
Am J Surg Pathol. 2007 Sep;31(9):1420-9
pubmed: 17721199
J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267
pubmed: 28982750
Urology. 2005 Dec;66(6 Suppl 1):4-34
pubmed: 16399414
J Urol. 2003 Jan;169(1):110-5; discussion 115
pubmed: 12478115
Am J Surg Pathol. 2010 Mar;34(3):418-22
pubmed: 20154589
Virchows Arch. 2012 Aug;461(2):149-56
pubmed: 22777576
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Urology. 2010 Sep;76(3):600-2
pubmed: 20394971
Eur Urol. 2004 Mar;45(3):292-6
pubmed: 15036673
Am J Surg Pathol. 2014 Aug;38(8):e20-34
pubmed: 25029121
Eur Urol. 2014 Apr;65(4):778-92
pubmed: 24373477
BJU Int. 2004 Dec;94(9):1258-62
pubmed: 15610101
Ann Diagn Pathol. 2007 Dec;11(6):395-401
pubmed: 18022122
J Urol. 2003 Oct;170(4 Pt 1):1085-7
pubmed: 14501697
Arch Ital Urol Androl. 2016 Mar 31;88(1):13-6
pubmed: 27072170

Auteurs

Oudai Hassan (O)

Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Belkiss Murati Amador (B)

Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Kara A Lombardo (KA)

Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD, USA.

Daniela Salles (D)

Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Fatima Cuello (F)

Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Alexander S Marwaha (AS)

Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Marcus J Daniels (MJ)

Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Max Kates (M)

Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD, USA.

Trinity J Bivalacqua (TJ)

Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD, USA.

Andres Matoso (A)

Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA. amatoso1@jhmi.edu.
Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA. amatoso1@jhmi.edu.
Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA. amatoso1@jhmi.edu.
Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD, USA. amatoso1@jhmi.edu.
The Johns Hopkins Hospital, The Weinberg Building, Rm. 2242, 401 N. Broadway Street, Baltimore, MD, 21231, USA. amatoso1@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH